Ceribell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions. Its core product is the Ceribell System, a point-of-care electroencephalography (EEG) platform designed for acute care settings. The system combines portable, rapidly deployable hardware with sophisticated AI-powered algorithms for clinical decision support. It has received FDA 510(k) clearance and holds multiple FDA Breakthrough Designations.
Central to its technology is the Clarity AI algorithm, which provides seizure detection within the Ceribell System with reported performance metrics of 95% sensitivity and 97% specificity. The company operates at a significant scale across the United States, with its system deployed in over 600 hospitals and used to assess more than 200,000 patients. The clinical impact is supported by 45 peer-reviewed publications.
The company's work involves developing and refining AI-driven diagnostic tools within the domains of electroencephalography and neurology. Its technology processes neurological data to assist clinicians in acute environments. Financially, the company reported $24.8 million in revenue for Q4 2025, representing a 34% year-over-year increase.
